Search Results

THINK Surgical, Inc., a leading innovator in the field of robotic surgery, is pleased to announce a collaborative project between Concordia University and THINK Surgical funded by the Natural Sciences and Engineering Research Council of Canada and MEDTEQ+.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Vistagen today announced that the company’s Chief Executive Officer, Shawn Singh, will lead a Concordia Live Webinar on the need for innovative approaches to mental health treatment.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Vistagen today announced that its Chief Executive Officer, Shawn Singh, will participate in a private executive roundtable on September 20th at the 2022 Concordia Annual Summit being held September 19-21, 2022, in New York City.

VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn K. Singh , will join U.S. Surgeon General, Vice Admiral Vivek H. Murthy, MD, MBA, at the 2022 Concordia Americas Summit to discuss America’s ongoing mental health crisis.

Monopar’s pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease

Pfizer is proud to announce that it is supporting a McMaster University-led study, through the Ontario Clinical Oncology Group, that aims to improve care for Canadians living with multiple myeloma.